The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
Women with early-stage HER2-positive breast cancer who achieved a pathologic complete response to neoadjuvant HER2-directed therapy experienced prolonged event-free survival and overall survival versus those who did not.
Neratinib was shown to have a numerical overall survival benefit in addition to improvements in invasive disease-free survival and central nervous system recurrence in patients with HER2-positive, hormone receptor–positive, early stage breast cancer.
The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.
A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.
Precision medicine advancements are opening a new chapter in the development of anticancer therapies that target the HER2 pathway, resulting in 3 approvals for breast cancer in less than a year and raising hopes for attacking other cancer types.
Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.